A Guide to Breast Cancer Treatment Paths

The treatment of breast cancer is a personalized journey that depends on factors such as the type of cancer, stage, hormone receptor status, and patient health. This guide outlines the main treatment options, including chemotherapy, surgery, radiation therapy, targeted therapies, immunotherapy, and supportive care.

1. Determining Your Treatment Path

Treatment decisions are influenced by:

• Cancer Type: Hormone receptor-positive, HER2-positive, Triple-Negative, etc.
• Stage: Localized, regional, or metastatic.
• Biomarkers: Presence of ER, PR, HER2, or BRCA mutations.
• Patient Factors: Overall health, age, and personal preferences.

2. Treatment Options by Type of Breast Cancer

Ovarian Suppression

• Who It’s For:
  • Pre-menopausal women with early-stage breast cancer and women with Hormone Receptor-Positive breast cancer undergoing chemotherapy.
  • Reduces estrogen levels to mimic a postmenopausal state, enhancing the effectiveness of hormone therapies or as an additional protective measure against recurrence.
• Drugs Used:
  • Goserelin (Zoladex), Leuprolide (Lupron).
• How It’s Administered:
  • Monthly or quarterly injections during chemotherapy and possibly for several years post-treatment.
• Benefits:
  • Protects ovarian function for women wishing to preserve fertility.
  • Reduces estrogen-driven cancer growth.
• Side Effects:
  • Hot flashes, night sweats, mood swings, bone thinning.

Hormone Receptor-Positive (HR-Positive) Breast Cancer

HR-positive cancers rely on hormones like estrogen (ER) and/or progesterone (PR) for growth.

A. Hormone Therapy

• Selective Estrogen Receptor Modulators (SERMs)
  • Example: Tamoxifen.
  • Use: Blocks estrogen receptors; effective for pre- and postmenopausal women.
• Aromatase Inhibitors (AIs)
  • Example: Anastrozole (Arimidex), Letrozole (Femara).
  • Use: Blocks estrogen production; typically for postmenopausal women.
• CDK4/6 Inhibitors
  • Example: Palbociclib (Ibrance), Ribociclib (Kisqali), Abemaciclib (Verzenio).
  • Use: Combined with hormone therapy for advanced HR-positive, HER2-negative cancers.

B. Chemotherapy

Chemotherapy may be required for aggressive cases:

• Criteria:
  • High Ki-67 Index (>20–30%).
  • Grade 3 tumors.
  • Significant lymph node involvement.
  • Large tumor size (>5 cm).

Common Chemotherapy Regimens:

• AC-T: Doxorubicin (Adriamycin) + Cyclophosphamide followed by Paclitaxel (Taxol).
• TC: Docetaxel (Taxotere) + Cyclophosphamide.
• Taxol (Paclitaxel) Followed by AC: Doxorubicin + Cyclophosphamide:
  • Taxol (Paclitaxel): Administered weekly or every three weeks to manage tumor size.
  • AC (Adriamycin + Cyclophosphamide): Administered after Taxol to target rapidly dividing cells.
• FEC-D: Fluorouracil (5-FU), Epirubicin, Cyclophosphamide followed by Docetaxel.

HER2-Positive Breast Cancer

HER2-positive cancers overexpress the HER2 protein, leading to aggressive growth. Targeted therapies have significantly improved outcomes.

A. Targeted Therapy

• Trastuzumab (Herceptin):
  • Blocks HER2 receptors to prevent tumor growth.
• Pertuzumab (Perjeta):
  • Combined with trastuzumab for dual HER2 blockade.
• Ado-Trastuzumab Emtansine (Kadcyla):
  • Antibody-drug conjugate combining trastuzumab with chemotherapy.
• Tucatinib and Neratinib:
  • Effective in advanced HER2-positive cases, including brain metastases.

B. Chemotherapy

• TCHP: Docetaxel, Carboplatin, Trastuzumab, Pertuzumab.
• AC-TH: Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab.

Triple-Negative Breast Cancer (TNBC)

TNBC lacks ER, PR, and HER2 receptors, making it aggressive and harder to treat. Treatment decisions often depend on individual risk factors, biomarker testing, and oncologist preference.

A. Immunotherapy with Chemotherapy (Keynote-522 Protocol)

Keynote-522 Protocol is now the recommended standard for early-stage TNBC.

• Overview:
  • Combines pembrolizumab (Keytruda), an immune checkpoint inhibitor, with chemotherapy in the neoadjuvant (pre-surgery) and adjuvant (post-surgery) settings.
• Components:
  • Neoadjuvant Phase: Pembrolizumab with carboplatin and paclitaxel.
  • Adjuvant Phase: Pembrolizumab maintenance therapy for up to one year.
• Benefits:
  • Improved pathologic complete response (pCR) rates and recurrence-free survival.
• Considerations:
  • Most oncologists now recommend Keynote-522, but access to immunotherapy may vary.

B. Dose-Dense Chemotherapy Path

Some oncologists may still recommend dose-dense chemotherapy, especially in cases where immunotherapy is not an option.

• Preferred Regimen:
  • Dose-Dense AC-T:
    • Doxorubicin (Adriamycin) + Cyclophosphamide followed by Paclitaxel (Taxol).
    • Administered on a dose-dense schedule (every two weeks) to shorten treatment duration.

C. PARP Inhibitors

• Use: For BRCA-mutated TNBC or high-risk cases.
• Examples:
  • Olaparib (Lynparza), Talazoparib.
• Mechanism: Target DNA repair pathways in cancer cells.

Inflammatory Breast Cancer (IBC)

IBC is rare and aggressive, requiring a multi-modal approach.

A. Neoadjuvant Chemotherapy

• Regimens: AC-T or TCHP for HER2-positive IBC.

B. Surgery

• Modified radical mastectomy.

C. Radiation Therapy

• Post-surgical high-dose radiation.

Metastatic Breast Cancer

Treatment aims to prolong life and improve quality of life.

A. Hormone Therapy (HR-Positive Disease)

• Aromatase inhibitors, SERMs, or CDK4/6 inhibitors.

B. Chemotherapy

• Single-Agent Chemotherapy:
  • Capecitabine, Paclitaxel, or Vinorelbine.
• Combination Regimens:
  • Used for aggressive disease progression.

C. Targeted Therapies

• HER2-Positive: Trastuzumab, Pertuzumab, Tucatinib.
• PIK3CA Mutation: Alpelisib with endocrine therapy.

3. Expanded Information on Surgery

Surgery is a cornerstone of breast cancer treatment, particularly for early-stage and localized disease. Types of surgeries include lumpectomy, mastectomy, sentinel lymph node biopsy, and reconstructive surgery.

See full details in the guide's surgery section.

4. Expanded Information on Radiation Therapy

Radiation therapy is used to destroy remaining cancer cells after surgery, shrink tumors before surgery, or manage advanced cancer symptoms.

See full details in the guide's radiation therapy section.

5. Key Questions to Ask Your Doctor

1. What specific treatments are recommended for my cancer type and stage?
2. How does Keynote-522 or other immunotherapy protocols apply to my case?
3. What are the potential side effects, and how can they be managed?
4. Are there clinical trials I qualify for?

Starting treatment and need help deciding what you need? Let Wellnest's Breast Cancer Treatment Essentials help guide you.